Key Highlights

  • Revenue was USD 5.3 million, up 6% from USD 5.0 million a year earlier.
  • Operating loss improved 15% year over year to USD 8 million.
  • Net loss was USD 8.8 million, compared with USD 10.5 million in the prior-year quarter.
  • Non-GAAP B2B2C gross Margin held near 80% for an 11th consecutive quarter.

DarioHealth (NASDAQ:DRIO) reported third-quarter 2026 Revenue of USD 5.3 million, against an estimate of USD 5.21 million. Loss per share was USD 0.73, against an estimate of a loss of USD 0.95. Revenue was up 6% from USD 5.0 million in the third quarter of 2025 and up 3% from USD 5.2 million in the second quarter of 2026.

The increase in third-quarter revenue came mainly from higher direct-to-consumer sales. For the nine months, revenue was USD 16.1 million, down 6.2% from USD 17.1 million, because of non-recurring revenue from a pharmaceutical partner recognized in the prior-year period, partly offset by growth from channel partners and direct-to-consumer sales.

Gross Margin, Expenses and Operating Loss

Cost of revenues was USD 2.2 million, up 8.7%, reflecting higher revenue and higher hardware and consumables costs tied to direct-to-consumer sales, partly offset by lower hosting costs. Gross margin was 59%, compared with 60% in the third quarter of 2025 and 62% in the second quarter of 2026. The company attributed the change to a smaller Tariff refund benefit and a higher direct-to-consumer mix, partly offset by lower hosting costs.

For the nine months, cost of revenues fell 10.1%, helped by lower technology amortization, lower hosting costs and an IEEPA tariff refund of USD 448 thousand recorded in the period. Non-GAAP B2B2C gross margin remained at approximately 80% for the eleventh consecutive quarter.

Operating expenses were USD 11.2 million, down 10% from USD 12.5 million a year earlier, and rose from the second quarter on higher stock-based compensation, mainly in general and administrative expense. The operating loss was USD 8 million, and non-GAAP operating loss narrowed to USD 5.3 million from USD 6 million. For the first nine months of 2026, operating expenses declined 17% and the operating loss improved 22%.

Net Loss, Cash and Funding

The net loss was USD 8.8 million, against USD 10.5 million. Management said it continues to apply AI inside its own operations as one of several contributors to lower operating costs.

At September 30, 2026, DarioHealth held approximately USD 27.8 million in cash and cash equivalents and USD 3.3 million in short-term deposits, compared with USD 21.8 million and USD 4.2 million at December 31, 2025. Stockholders' Equity was USD 71.3 million. Cumulative losses since inception in August 2011 totaled USD 477.1 million.

The filing states that the company has not yet established a stable recurring source of revenue sufficient to cover its operating costs and that it has incurred cumulative losses since inception. Since inception it has financed operations primarily through equity and other financing.

Reported Measures in the Filing

The report separates GAAP and non-GAAP measures, and a reconciliation appears in the Earnings press release. The gross margin series of 59%, 60% and 62% across the three periods cited, together with the B2B2C gross margin of approximately 80%, are the margin figures management presented.

Operating expense, operating loss and net loss are each reported against the prior-year quarter, and the nine-month Operating Expense and operating loss comparisons are reported alongside them. Cash, short-term deposits and cumulative losses are the Balance Sheet items disclosed in the Liquidity discussion.